Resumen de acción S2P Simcere Pharmaceutical Group Limited se dedica a la investigación, desarrollo, fabricación y venta de productos farmacéuticos para distribuidores y cadenas de farmacias y otros fabricantes de productos farmacéuticos en China. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Simcere Pharmaceutical Group Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Simcere Pharmaceutical Group Precios históricos de las acciones Precio actual de la acción HK$0.82 Máximo en las últimas 52 semanas HK$0.89 Mínimo de 52 semanas HK$0.57 Beta 0.41 Cambio en 1 mes -0.61% Variación en 3 meses 3.80% Cambio de 1 año 34.43% Variación en 3 años -10.87% Variación en 5 años n/a Variación desde la OPV -43.45%
Noticias y actualizaciones recientes
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for Sim0505 (CDH6 Antibody-Drug Conjugate) Issued by the National Medical Products Administration Jan 06
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05 Ver más actualizaciones
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for Sim0505 (CDH6 Antibody-Drug Conjugate) Issued by the National Medical Products Administration Jan 06
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 25
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
Now 22% overvalued Aug 03
Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration Jul 17
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug Jul 11
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China Jun 25 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024. Jun 20
Upcoming dividend of CN¥0.16 per share Jun 11
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China Jun 01
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong May 23
Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.36 in FY 2022) Apr 26
Dividend of CN¥0.16 announced Mar 22 Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China Mar 16
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration Mar 13
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500 Mar 12
Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 Feb 20
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19 Jan 19
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets Jan 12
Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Dec 27
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration Dec 04
Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration Nov 30
Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Oct 31
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration Oct 17
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Sep 25
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 28
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 23
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jul 01 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jun 30
Co-Founder recently sold €271k worth of stock Jun 21
Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023 Jun 16
Upcoming dividend of CN¥0.16 per share at 2.3% yield Jun 12
Co-Founder recently sold €360k worth of stock May 01
Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.58 in FY 2021) Apr 19
Investor sentiment improves as stock rises 19% Apr 13
Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration Jan 30
Investor sentiment deteriorated over the past week Jan 20
Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director Jan 19
Now 30% undervalued Jan 18
Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration Jan 17
Co-Founder recently bought €957k worth of stock Jan 11 Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023
Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration Dec 30
Investor sentiment improved over the past week Dec 30
Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment Dec 21
Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment Dec 19
Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study Dec 03
Insufficient new directors Nov 16
Simcere Pharmaceutical Group Limited Announces Executive Changes Nov 10
Investor sentiment improved over the past week Nov 03
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application Oct 28
Investor sentiment improved over the past week Oct 15
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 06
First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021) Sep 01
Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes Sep 01
Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 02
Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China Jul 19
Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration Jul 14
Investor sentiment improved over the past week Jul 09
Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022 Jun 25
Upcoming dividend of CN¥0.15 per share Jun 21 Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2021 Jun 02
Simcere Pharmaceutical Group Limited Announces Appointment of Tang Renhong as Co-Chief Executive Officer May 26
Investor sentiment improved over the past week May 18
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0417 (3Cl) Issued by the National Medical Products Administration May 17
CFO & Executive Director recently bought €66k worth of stock Apr 30
Full year 2021 earnings released: EPS: CN¥0.58 (vs CN¥0.28 in FY 2020) Apr 28
Less than half of directors are independent Apr 27
Simcere Pharmaceutical Group Limited Obtains Permission from the National Medical Products Administration of China to Conduct Clinical Trials Apr 01
Investor sentiment improved over the past week Mar 21
Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease Mar 01
Simcere Pharmaceutical Group Announces Primary Endpoint Met in Phase III Clinical Trial of Trilaciclib in Chinese Patients with Small Cell Lung Cancer Feb 24
Simcere Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021 Feb 22
Simcere Pharmaceuticals Announces Appointment of Bijoyesh Mookerjee as Chief Medical Officer, Oncology Feb 08
Simcere Pharmaceutical Group Limited Announces the Approval of Investigational New Drug for SIM0235 Issued by U.S. Food and Drug Administration Jan 31
Investor sentiment improved over the past week Jan 18
Center for Drug Evaluation of the National Medical Products Administration of China Includes Simcere Pharmaceutical Group Limited's Trilaciclib Injection as a Priority Review Drug Dec 23 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0235 Issued by National Medical Products Administration
Simcere Pharmaceutical Group Limited Announces Conditional Approval on the Marketing of Enweida (Envafolimab) in China by The national Medical Products Administration Nov 27
Investor sentiment improved over the past week Nov 19 Rentabilidad de los accionistas S2P DE Pharmaceuticals Mercado DE 7D -2.4% -3.9% -0.02% 1Y 34.4% -12.4% 15.1%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: S2P superó a la industria German Pharmaceuticals, que obtuvo un rendimiento del -12.4% el año pasado.
Rentabilidad vs. Mercado: S2P superó al mercado German, que obtuvo un rendimiento del 15.1% el año pasado.
Volatilidad de los precios Is S2P's price volatile compared to industry and market? S2P volatility S2P Average Weekly Movement 5.7% Pharmaceuticals Industry Average Movement 5.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: S2P no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: La volatilidad semanal de S2P (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Simcere Pharmaceutical Group Limited se dedica a la investigación, desarrollo, fabricación y venta de productos farmacéuticos para distribuidores y cadenas de farmacias y otros fabricantes de productos farmacéuticos en China. La empresa se centra en diversas áreas terapéuticas, como oncología, sistema nervioso central, autoinmunes, antiinfecciosas, cardiovasculares y otras. Sus principales productos son Sanbexin, una solución inyectable concentrada de edaravona y dexborneol; Endostar, una inyección de endostatina humana recombinante; ENWEIDA, una inyección de envafolimab; COSELA, un clorhidrato de trilaciclib inyectable; Iremod, un comprimido de iguratimod; y XIANNUOXIN, un simnotrelvir/ritonavir en comprimidos.
Mostrar más Resumen de fundamentos de Simcere Pharmaceutical Group Limited ¿Cómo se comparan los beneficios e ingresos de Simcere Pharmaceutical Group con su capitalización de mercado? Estadísticas fundamentales de S2P Capitalización bursátil €2.08b Beneficios(TTM ) -€146.43m Ingresos (TTM ) €842.15m
2.5x Ratio precio-ventas (PS)
-14.2x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de S2P Ingresos CN¥6.34b Coste de los ingresos CN¥1.45b Beneficio bruto CN¥4.88b Otros gastos CN¥5.99b Beneficios -CN¥1.10b
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.44 Margen bruto 77.05% Margen de beneficio neto -17.39% Ratio deuda/patrimonio 14.5%
¿Cómo se ha desempeñado S2P a largo plazo?
Ver rendimiento histórico y comparativa Dividendos
2.5% Rentabilidad actual por dividendo
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/02/07 20:09 Precio de las acciones al final del día 2025/02/07 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github .
Fuentes analistas Simcere Pharmaceutical Group Limited está cubierta por 16 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Sharon Shi BOCI Research Ltd. Shaojing Tong BofA Global Research Bo Yu China International Capital Corporation Limited
Mostrar 13 más analistas 